Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
Gordon Cook(University of Leeds), Jonathan Sive(University College London Hospitals NHS Foundation Trust), A. John Ashcroft(Mid Yorkshire Hospitals NHS Trust), Simon Stern(Epsom and St Helier University Hospitals NHS Trust), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Sarah Henshaw(University of Guelph), Richard Soutar(NHS Greater Glasgow and Clyde), Graham Jackson(Newcastle College), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Neil Rabin(University College London), Rachel Hall(Welsh Government)
Cited by 111
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564